Marinus Pharmaceuticals (NASDAQ:MRNS) PT Lowered to $10.00

Marinus Pharmaceuticals (NASDAQ:MRNS) had its price objective decreased by Truist Financial from $25.00 to $10.00 in a research note published on Wednesday morning, Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.

MRNS has been the subject of several other research reports. Royal Bank of Canada reissued a sector perform rating and set a $3.00 price objective (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday, April 15th. Oppenheimer reiterated a market perform rating and issued a $9.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. Robert W. Baird reiterated a neutral rating on shares of Marinus Pharmaceuticals in a report on Tuesday. StockNews.com downgraded Marinus Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, March 6th. Finally, Cantor Fitzgerald reiterated an overweight rating and issued a $28.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, April 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of Hold and an average price target of $16.07.

Marinus Pharmaceuticals Stock Performance

Shares of Marinus Pharmaceuticals stock opened at $1.38 on Wednesday. The company has a debt-to-equity ratio of 5.68, a current ratio of 4.07 and a quick ratio of 4.01. The business has a fifty day simple moving average of $8.37 and a two-hundred day simple moving average of $8.36. Marinus Pharmaceuticals has a 12 month low of $1.11 and a 12 month high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The firm had revenue of $7.19 million for the quarter, compared to analysts’ expectations of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. During the same period in the prior year, the business posted ($0.76) EPS. On average, research analysts expect that Marinus Pharmaceuticals will post -2.23 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Marinus Pharmaceuticals by 1.2% in the third quarter. Vanguard Group Inc. now owns 2,577,475 shares of the biopharmaceutical company’s stock worth $20,749,000 after purchasing an additional 31,233 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its position in Marinus Pharmaceuticals by 69.5% in the third quarter. Schonfeld Strategic Advisors LLC now owns 253,412 shares of the biopharmaceutical company’s stock worth $2,040,000 after purchasing an additional 103,935 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Marinus Pharmaceuticals by 6.3% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock worth $23,381,000 after purchasing an additional 173,226 shares during the last quarter. Jennison Associates LLC boosted its position in Marinus Pharmaceuticals by 58.4% in the third quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock worth $23,791,000 after purchasing an additional 1,089,913 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at about $134,000. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.